April 9, 2018 09:25 AM EDT
R&D

Ab­b­Vie’s promised rheuma­toid arthri­tis block­buster upadac­i­tinib hits its marks in an­oth­er PhI­II — this time with­out any deaths

John Carroll

Editor & Founder

Ab­b­Vie $AB­BV has post­ed an­oth­er pos­i­tive batch of Phase III da­ta on its JAK1 in­hibitor upadac­i­tinib, hit­ting the pri­ma­ry and key sec­ondary end­points in their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times